Gilgamesh Pharmaceuticals

Executive Summary

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company pioneering novel, best-in-class small molecules inspired by psychedelic compounds for the treatment of mental illnesses. Founded in 2021 and headquartered in New York, the company aims to move beyond symptom management by developing rapid-acting and durable therapies that target underlying disease mechanisms. Their lead program, GM-1020, is a non-hallucinogenic neuroplasticity modulator currently in Phase 1 trials for major depressive disorder. This molecule is designed to retain the therapeutic benefits of psychedelics while minimizing adverse effects, potentially enabling at-home oral dosing without the need for clinical supervision. Preclinical data have shown rapid and sustained antidepressant effects in animal models, supporting the potential for a paradigm shift in psychiatric care. The company's pipeline also includes GM-2020, a second-generation compound for anxiety and substance use disorders, as well as earlier-stage candidates for neuropsychiatric indications. Gilgamesh is backed by experienced scientific founders and has secured venture funding to advance its programs through clinical proof-of-concept. The company's innovative approach positions it among a select group of biotechs exploring the therapeutic potential of psychedelic-inspired psychoplastogens.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 GM-1020 multiple ascending dose (MAD) data readout75% success
• Q2 2026IND filing for GM-2020 (anxiety indication)80% success
• Q3 2026Preclinical data presentation for next-generation psychoplastogen program90% success